Noninvasive prenatal testing (NIPT)
Panorama is a screening test, which means that this test does not make a final diagnosis. A high risk result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based upon the screening result alone. All medical decisions should be made after discussion with your healthcare provider regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.
*SNP, single nucleotide polymorphism
Watch our 30-minute webinar to learn about:
- Published findings from SMART, the largest prospective NIPT study with over 20,000 patients enrolled
- How SNP-based NIPT performed in a large, diverse, real-world environment compared to validation study results
- Potential impact of these findings on expanded NIPT screening guidelines
- Improving SNP-based NIPT performance with the use of artificial intelligence
Why choose Panorama for fetal genetic testing?
Clinical advantages of genetic testing for pregnancy:
- Panorama detects conditions that other tests cannot, including molar pregnancy, triploidy and vanishing twin.4
- Panorama screens for Down syndrome with an accuracy rate greater than 99%.*1,5-7
- Panorama is the only test that differentiates between pregnant person’s and fetal DNA, which helps avoid false positives and false negatives.1,5-9
- Panorama is the only NIPT that can assess zygosity and individual fetal fraction* in twin pregnancies.**10
- Panorama has a 22q11.2 deletion sensitivity of 83%. This common and potentially severe microdeletion impacts pregnancies equally regardless of maternal age.2
- Panorama can be performed for singleton, twin, egg donor, and gestational carrier pregnancies.9
Findings from the SMART study have been published in the American Journal of Obstetrics and Gynecology
Recent ACOG guidelines support NIPT for all pregnancies1
- Recommends NIPT as an option to be “discussed and offered to all patients early in pregnancy, regardless of maternal age or baseline risk.”
- Endorses cfDNA as the “most sensitive and specific screening test for the common fetal aneuploidies.”
- Highlights unique advantages of SNP-based NIPT, including triploidy detection and unique twins capabilities such as zygosity detection and individual fetal fraction measurements.
Panorama’s SNP-enabled capabilities make every result matter
Vanishing twin detection4
Recognized by the American College of Obstetricians and Gynecologist (ACOG) as a major cause of NIPT false positives8
Maternal X mosaicism detection11
As stated in ACOG practice bulletin 226, SNP-based NIPT (Panorama) is the only noninvasive method that can identify triploidy8
Find out what is new in the latest version of Panorama, Panorama AI*
Clinically validated differentiation for twin pregnancies*
Recognized by the International Society for Prenatal Diagnosis (ISPD) as an important element in evaluating NIPT results for twins12
Individual fetal fraction for dizygotic twins10;13
An important metric necessary to interpret the reliability of NIPT results; ACOG recognizes that, without this measurement, aneuploidy could go undetected if the affected twin has low fetal fraction8
Individual fetal sex10
Panorama has zero fetal sex errors in published validation studies for both singletons and twins5-7,10
Other conditions screened9
- Trisomy 21
- Trisomy 18
- Trisomy 13
- Sex chromosome trisomies (reported when seen)†
- 22q11.2 deletion syndrome (optional)†
Is Panorama right for you?
We’re here to help you find out
1Dar et al. Am J Obstet Gynecol. Epub prior to publication. https://doi.org/10.1016/j.ajog.2022.01.002
2Dar et al. Am J Obstet Gynecol. Epub prior to publication. https://doi.org/10.1016/j.ajog.2022.01.019
3Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021.
4Nicolaides et al. Fetal Diagn Ther. 2014;35(3):212-7.
5Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8.
6Nicolaides et al. Prenat Diagn. 2013 June; 33(6):575-9.
7Ryan et al. Fetal Diagn Ther. 2016;40(3):219-223.
8ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
9Natera internal data on file.
10Norwitz et al. J Clin Med. 2019 Jun; 8:937.
11Martin KA et al. Am J Obstet Gynecol MFM. 2020;2:100152.
12Palomaki GE, et al. Prenat Diagn. 2020 Oct 5. doi: 10.1002/pd.5832. [Epub ahead of print].
13Hedriana H et al. Prenat Diagn. 2020 Jan;40(2):179-184.
14Society for Maternal-Fetal Medicine, Clinical guideline: Twin-twin transfusion syndrome, Jan 2013.
15American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine, practice bulletin #169, Oct 2016.
16Oldenburg et al. Ultrasound Obstet Gynecol. 2012 Jan;39(1); 39: 69–74.
17Chasen, Chervenak (2017). Twin pregnancy: Prenatal issues. In T. Post (Ed.), UpToDate. Waltham, Mass.: UpToDate. Retrieved from www.uptodate.com
18Cunningham et al. Williams Obstetrics. 24th edition. New York: McGraw-Hill Education, 2014.
*CA residents: Trisomies 21, 18, and 13, as well as fetal sex, are screened using Natera’s Vasistera NIPT or other approved NIPTs through the California Prenatal Screening program. Vasistera also assesses zygosity and individual fetal fraction in dizygotic twins. In California, Panorama is only offered as a supplemental NIPT for conditions not screened by Vasistera (for singleton pregnancies only).
** For dizygotic (nonidentical) twins only.
† For identical twins only.